Citation:Xu YP, Li B, Xu XL, Mao WM 2015
From Cancer Guidelines Wiki
Citation
Xu YP, Li B, Xu XL, Mao WM. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis. Medicine (Baltimore) 2015 Jun;94(23):e879 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26061306.
Critical appraisals
Compare quality appraisals for each clinical question
- [[Clinical question:What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?|Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</span></span></span>»]] (compare critical appraisals)
- [[Clinical question:What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC?, Clinical question:What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?|Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC?</span>, <span class="smw-value">Clinical question:What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?</span></span></span></span>»]] (compare critical appraisals)